{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:23:12Z","timestamp":1794208992085,"version":"4.8.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01006-0","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T09:04:24Z","timestamp":1754643864000},"page":"1595-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors"],"prefix":"10.1038","volume":"6","author":[{"given":"Elizabeth D.","family":"Lightbody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle T.","family":"Firer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-4274","authenticated-orcid":false,"given":"Michael P.","family":"Agius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-3729","authenticated-orcid":false,"given":"Ankit K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-5984","authenticated-orcid":false,"given":"Hadley","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nersesian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5826-3554","authenticated-orcid":false,"given":"Tim","family":"Coorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nang Kham","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Boehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5726","authenticated-orcid":false,"given":"Michelle P.","family":"Aranha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Rahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-7212","authenticated-orcid":false,"given":"Yoshinobu","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hevenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Towle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Cea-Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Vinyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-015X","authenticated-orcid":false,"given":"Daniel","family":"Heilpern-Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"El-Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Ready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Marinac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR3","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"1006_CR4","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418\u20135422 (2009).","journal-title":"Blood"},{"key":"1006_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"1006_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40584-4","volume":"14","author":"L John","year":"2023","unstructured":"John, L. et al. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat. Commun. 14, 5011 (2023).","journal-title":"Nat. Commun."},{"key":"1006_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28266-z","volume":"13","author":"M Merz","year":"2022","unstructured":"Merz, M. et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat. Commun. 13, 807 (2022).","journal-title":"Nat. Commun."},{"key":"1006_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche, L. et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat. Commun. 13, 4517 (2022).","journal-title":"Nat. Commun."},{"key":"1006_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2012.237","volume":"27","author":"G Bianchi","year":"2013","unstructured":"Bianchi, G. et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 27, 680\u2013685 (2013).","journal-title":"Leukemia"},{"key":"1006_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood.V88.1.289.289","volume":"88","author":"D Billadeau","year":"1996","unstructured":"Billadeau, D. et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88, 289\u2013296 (1996).","journal-title":"Blood"},{"key":"1006_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","volume":"13","author":"AK Dutta","year":"2023","unstructured":"Dutta, A. K. et al. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 13, 348\u2013363 (2023).","journal-title":"Cancer Discov."},{"key":"1006_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.15003","volume":"180","author":"B Foulk","year":"2018","unstructured":"Foulk, B. et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br. J. Haematol. 180, 71\u201381 (2018).","journal-title":"Br. J. Haematol."},{"key":"1006_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores, L. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 8, 117 (2018).","journal-title":"Blood Cancer J."},{"key":"1006_CR14","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1182\/blood.V88.5.1780.1780","volume":"88","author":"TE Witzig","year":"1996","unstructured":"Witzig, T. E. et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88, 1780\u20131787 (1996).","journal-title":"Blood"},{"key":"1006_CR15","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini, L. et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 3120\u20133131 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.117","volume":"6","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty, R. et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 6, e512 (2016).","journal-title":"Blood Cancer J."},{"key":"1006_CR17","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"JJ Garces","year":"2022","unstructured":"Garces, J. J. et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J. Clin. Oncol. 40, 3151\u20133161 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.25709","volume":"95","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves, W. I. et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am. J. Hematol. 95, 310\u2013315 (2020).","journal-title":"Am. J. Hematol."},{"key":"1006_CR19","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/leu.2014.98","volume":"28","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves, W. I. et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 28, 2060\u20132065 (2014).","journal-title":"Leukemia"},{"key":"1006_CR20","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.21.01217","volume":"40","author":"D Hofste Op Bruinink","year":"2022","unstructured":"Hofste Op Bruinink, D. et al. Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile. J. Clin. Oncol. 40, 3132\u20133150 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek, T. et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J. Clin. Oncol. 41, 1383\u20131392 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR22","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","volume":"23","author":"S Kumar","year":"2005","unstructured":"Kumar, S. et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J. Clin. Oncol. 23, 5668\u20135674 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR23","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski, G. S. et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106, 2276\u20132279 (2005).","journal-title":"Blood"},{"key":"1006_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","volume":"97","author":"AC Rawstron","year":"1997","unstructured":"Rawstron, A. C. et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97, 46\u201355 (1997).","journal-title":"Br. J. Haematol."},{"key":"1006_CR25","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","volume":"134","author":"L Sanoja-Flores","year":"2019","unstructured":"Sanoja-Flores, L. et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 134, 2218\u20132222 (2019).","journal-title":"Blood"},{"key":"1006_CR26","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","volume":"28","author":"R Termini","year":"2022","unstructured":"Termini, R. et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin. Cancer Res. 28, 4771\u20134781 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1006_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7037","volume":"8","author":"JG Lohr","year":"2016","unstructured":"Lohr, J. G. et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci. Transl. Med. 8, 363ra147 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1006_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier, S. et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat. Commun. 9, 1691 (2018).","journal-title":"Nat. Commun."},{"key":"1006_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","volume":"19","author":"Y Mishima","year":"2017","unstructured":"Mishima, Y. et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 19, 218\u2013224 (2017).","journal-title":"Cell Rep."},{"key":"1006_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"JJ Garces","year":"2020","unstructured":"Garces, J. J. et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia 34, 589\u2013603 (2020).","journal-title":"Leukemia"},{"key":"1006_CR31","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"1006_CR32","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S2152-2650(24)01881-0","volume":"24","author":"E Lightbody","year":"2024","unstructured":"Lightbody, E. et al. OA-40 SWIFT-Seq: single-cell RNA sequencing of circulating tumor cells as a comprehensive clinically applicable liquid biopsy test for patients with multiple myeloma and its precursor conditions. Clin. Lymphoma Myeloma Leuk. 24, S25\u2013S26 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1006_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33944-z","volume":"13","author":"R Boiarsky","year":"2022","unstructured":"Boiarsky, R. et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat. Commun. 13, 7040 (2022).","journal-title":"Nat. Commun."},{"key":"1006_CR34","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1182\/blood.2024025643","volume":"145","author":"MC Da Vi\u00e1","year":"2025","unstructured":"Da Vi\u00e1, M. C. et al. Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma. Blood 145, 3124\u20133138 (2025).","journal-title":"Blood"},{"key":"1006_CR35","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang, M. et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41, 1032\u20131047.e4 (2023).","journal-title":"Cancer Cell"},{"key":"1006_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22804-x","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat. Commun. 12, 2559 (2021).","journal-title":"Nat. Commun."},{"key":"1006_CR37","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824 (2024).","journal-title":"Am. J. Hematol."},{"key":"1006_CR38","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","volume":"57","author":"J-B Alberge","year":"2025","unstructured":"Alberge, J.-B. et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat. Genet. 57, 1493\u20131503 (2025).","journal-title":"Nat. Genet."},{"key":"1006_CR39","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"1006_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","volume":"41","author":"T Gao","year":"2023","unstructured":"Gao, T. et al. Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes. Nat. Biotechnol. 41, 417\u2013426 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1006_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/ijlh.13887","volume":"44","author":"G Jain","year":"2022","unstructured":"Jain, G. et al. Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. Int. J. Lab. Hematol. 44, 837\u2013845 (2022).","journal-title":"Int. J. Lab. Hematol."},{"key":"1006_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00951-2","volume":"13","author":"J Oskarsson","year":"2023","unstructured":"Oskarsson, J. et al. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: proposal for a bone marrow quality index. Blood Cancer J. 13, 177 (2023).","journal-title":"Blood Cancer J."},{"key":"1006_CR43","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","volume":"2","author":"MA Aljama","year":"2018","unstructured":"Aljama, M. A. et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2, 3149\u20133154 (2018).","journal-title":"Blood Adv."},{"key":"1006_CR44","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","volume":"81","author":"PR Greipp","year":"1993","unstructured":"Greipp, P. R. et al. Plasma cell labeling index and \u03b22-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81, 3382\u20133387 (1993).","journal-title":"Blood"},{"key":"1006_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajh.20125","volume":"77","author":"S Kumar","year":"2004","unstructured":"Kumar, S., Rajkumar, S. V., Greipp, P. R. & Witzig, T. E. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am. J. Hematol. 77, 7\u201311 (2004).","journal-title":"Am. J. Hematol."},{"key":"1006_CR46","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.ajpath.2012.07.020","volume":"181","author":"B Paiva","year":"2012","unstructured":"Paiva, B. et al. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am. J. Pathol. 181, 1870\u20131878 (2012).","journal-title":"Am. J. Pathol."},{"key":"1006_CR47","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","volume":"97","author":"DP Steensma","year":"2001","unstructured":"Steensma, D. P. et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 97, 2522\u20132523 (2001).","journal-title":"Blood"},{"key":"1006_CR48","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva, B. et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 122, 3591\u20133598 (2013).","journal-title":"Blood"},{"key":"1006_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"1006_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle, E. M. et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat. Commun. 12, 293 (2021).","journal-title":"Nat. Commun."},{"key":"1006_CR51","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 38, 2380\u20132389 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR52","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2020","unstructured":"Misund, K. et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 34, 322\u2013326 (2020).","journal-title":"Leukemia"},{"key":"1006_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0","volume":"12","author":"B Oben","year":"2021","unstructured":"Oben, B. et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat. Commun. 12, 1861 (2021).","journal-title":"Nat. Commun."},{"key":"1006_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze, A. et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 13, 160 (2023).","journal-title":"Blood Cancer J."},{"key":"1006_CR55","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa, L. J. et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 5, 3748\u20133759 (2021).","journal-title":"Blood Adv."},{"key":"1006_CR56","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser, M. F. et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J. Clin. Oncol. 41, 3945\u20133955 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt, L. B. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J. Clin. Oncol. 42, 26\u201337 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1006_CR58","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.26269","volume":"96","author":"MH Sidiqi","year":"2021","unstructured":"Sidiqi, M. H. et al. Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials. Am. J. Hematol. 96, 1131\u20131136 (2021).","journal-title":"Am. J. Hematol."},{"key":"1006_CR59","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N. Engl. J. Med. 392, 1777\u20131788 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR60","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"1006_CR62","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget, S. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat. Genet. 56, 1878\u20131889 (2024).","journal-title":"Nat. Genet."},{"key":"1006_CR63","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar, S. et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119, 2100\u20132105 (2012).","journal-title":"Blood"},{"key":"1006_CR64","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41587-023-01863-z","volume":"42","author":"F Muyas","year":"2023","unstructured":"Muyas, F. et al. De novo detection of somatic mutations in high-throughput single-cell profiling data sets. Nat. Biotechnol. 42, 758\u2013767 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1006_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","volume":"571","author":"AS Nam","year":"2019","unstructured":"Nam, A. S. et al. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature 571, 355\u2013360 (2019).","journal-title":"Nature"},{"key":"1006_CR66","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281.e24 (2019).","journal-title":"Cell"},{"key":"1006_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2192-6","volume":"16","author":"CR Lindsay","year":"2016","unstructured":"Lindsay, C. R. et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 16, 168 (2016).","journal-title":"BMC Cancer"},{"key":"1006_CR68","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-17-2312","volume":"24","author":"MJM Magbanua","year":"2018","unstructured":"Magbanua, M. J. M. et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance). Clin. Cancer Res. 24, 1486\u20131499 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1006_CR69","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","volume":"34","author":"JJ Garces","year":"2020","unstructured":"Garces, J. J. et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia 34, 3007\u20133018 (2020).","journal-title":"Leukemia"},{"key":"1006_CR70","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","volume":"133","author":"A Thakurta","year":"2019","unstructured":"Thakurta, A. et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 133, 1217\u20131221 (2019).","journal-title":"Blood"},{"key":"1006_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55308-5","volume":"16","author":"O Nadeem","year":"2025","unstructured":"Nadeem, O. et al. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat. Commun. 16, 358 (2025).","journal-title":"Nat. Commun."},{"key":"1006_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"1006_CR73","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/bioinformatics\/btz698","volume":"36","author":"AS Bais","year":"2020","unstructured":"Bais, A. S. & Kostka, D. scds: computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics 36, 1150\u20131158 (2020).","journal-title":"Bioinformatics"},{"key":"1006_CR74","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979 (2021).","journal-title":"F1000Res"},{"key":"1006_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"1006_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56323-w","volume":"16","author":"R Sklavenitis-Pistofidis","year":"2025","unstructured":"Sklavenitis-Pistofidis, R. et al. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom\u2019s macroglobulinemia. Nat. Commun. 16, 1480 (2025).","journal-title":"Nat. Commun."},{"key":"1006_CR77","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"1006_CR78","doi-asserted-by":"publisher","first-page":"eabg2538","DOI":"10.1126\/science.abg2538","volume":"372","author":"LM Morton","year":"2021","unstructured":"Morton, L. M. et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 372, eabg2538 (2021).","journal-title":"Science"},{"key":"1006_CR79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"1006_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"1006_CR81","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.2024025102","volume":"146","author":"R Sklavenitis-Pistofidis","year":"2025","unstructured":"Sklavenitis-Pistofidis, R. et al. Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of multiple myeloma with 1q. Blood 146, 89\u2013103 (2025).","journal-title":"Blood"},{"key":"1006_CR82","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/bioinformatics\/btq706","volume":"27","author":"KP Schliep","year":"2011","unstructured":"Schliep, K. P. phangorn: phylogenetic analysis in R. Bioinformatics 27, 592\u2013593 (2011).","journal-title":"Bioinformatics"},{"key":"1006_CR83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2018","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2018).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01006-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:03:53Z","timestamp":1758809033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01006-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01006-0","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T., D.T.F., T.W., M.P. Agius, A.K.D., H.B., S.K., J.-B.A., T.C., S.N., N.K.S., C.J.B., M.P. Aranha, M.R., Y.K., L.H., K.T., E.H., J.P., M.D., K.A.W., C.J.C.-C., G.F., M.E.V., D.H.-M., H.E.-K., A.C., J.E.R. and C.R.M. declare no competing interests. R.S.-P. is a co-founder, equity holder and consultant for PreDICTA Biosciences, a precision oncology company integrating multiomics and liquid biopsies to develop diagnostic and therapeutic products. N.J.H. is a consultant for Constellation Pharmaceuticals. G.G. is an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSIDetect and MinumuMM-seq. G.G. receives research funds from IBM, Pharmacyclics and Ultima Genomics, and is a founder of, consultant for and holds privately held equity in Scorpion Therapeutics; he is also a founder of and holds privately held equity in PreDICTA Biosciences. I.M.G. has a consulting or advisory role with AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, The Binding Site and Window Therapeutics; has received speaker fees from Vor Biopharma and Veeva Systems, Inc.; is a co-founder, equity holder and consultant for PreDICTA Biosciences; and her spouse is the CMO and equity holder of Disc Medicine. E.D.L., R.S.-P., G.G. and I.M.G. have submitted a patent application related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}